Chronic Corticosteroid Use as a Risk Factor for Perioperative Complications in Patients Undergoing Total Joint Arthroplasty.
Journal
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews
ISSN: 2474-7661
Titre abrégé: J Am Acad Orthop Surg Glob Res Rev
Pays: United States
ID NLM: 101724868
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
entrez:
17
7
2020
pubmed:
17
7
2020
medline:
26
10
2021
Statut:
ppublish
Résumé
Osteoarthritis may be caused by or concurrent with diseases such as rheumatoid arthritis or systemic lupus erythematosus, which rely on chronic corticosteroids regimens for treatment. If a total knee or hip arthroplasty is needed, this chronic treatment method has been associated with poorer surgical outcomes. A retrospective analysis of data collected by the American College of Surgeons National Surgical Quality Improvement Program was conducted. The Current Procedural Terminology codes were used to identify 403,566 total knee arthroplasty and total hip arthroplasty patients who were then stratified by the use of chronic corticosteroids for univariate analysis. Forteen thousand seven hundred seventy-four of the patients identified were prescribed chronic corticosteroid regimens. A statistically significant difference was observed in perioperative complications for patients prescribed with corticosteroids, including higher rates of surgical site infection (P = 0.0001), occurrence of deep incisional surgical site infection (P < 0.0001), occurrences of organ space surgical site infection (P < 0.0001), wound dehiscence (P < 0.0001), general would infection (P < 0.0001), pneumonia (P < 0.0001), occurrences of unplanned intubation (P = 0.0002), urinary tract infection (P < 0.0001), and readmission (P < 0.0001). No statistically significant difference was observed in the 30-day mortality between the 2 groups (0.63), venous thromboembolic event (0.42), cerebrovascular accident (0.12), myocardial infarction (0.49), cardiac arrest (0.098), deep vein thrombosis (0.17), or sepsis (0.52). Many of the notable differences in complications may be directly attributed to the immunosuppressive nature of corticosteroids. With increased knowledge of which perioperative complications to monitor, surgeons can tailor treatment strategies to this population that reduce morbidity and improve outcomes.
Sections du résumé
BACKGROUND
Osteoarthritis may be caused by or concurrent with diseases such as rheumatoid arthritis or systemic lupus erythematosus, which rely on chronic corticosteroids regimens for treatment. If a total knee or hip arthroplasty is needed, this chronic treatment method has been associated with poorer surgical outcomes.
METHODS
A retrospective analysis of data collected by the American College of Surgeons National Surgical Quality Improvement Program was conducted. The Current Procedural Terminology codes were used to identify 403,566 total knee arthroplasty and total hip arthroplasty patients who were then stratified by the use of chronic corticosteroids for univariate analysis.
RESULTS
Forteen thousand seven hundred seventy-four of the patients identified were prescribed chronic corticosteroid regimens. A statistically significant difference was observed in perioperative complications for patients prescribed with corticosteroids, including higher rates of surgical site infection (P = 0.0001), occurrence of deep incisional surgical site infection (P < 0.0001), occurrences of organ space surgical site infection (P < 0.0001), wound dehiscence (P < 0.0001), general would infection (P < 0.0001), pneumonia (P < 0.0001), occurrences of unplanned intubation (P = 0.0002), urinary tract infection (P < 0.0001), and readmission (P < 0.0001). No statistically significant difference was observed in the 30-day mortality between the 2 groups (0.63), venous thromboembolic event (0.42), cerebrovascular accident (0.12), myocardial infarction (0.49), cardiac arrest (0.098), deep vein thrombosis (0.17), or sepsis (0.52).
CONCLUSION
Many of the notable differences in complications may be directly attributed to the immunosuppressive nature of corticosteroids. With increased knowledge of which perioperative complications to monitor, surgeons can tailor treatment strategies to this population that reduce morbidity and improve outcomes.
Identifiants
pubmed: 32672719
doi: 10.5435/JAAOSGlobal-D-20-00001
pii: 01979360-202007000-00001
pmc: PMC7366416
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Langues
eng
Pagination
e2000001Références
Arch Orthop Trauma Surg. 2013 May;133(5):675-87
pubmed: 23558519
J Bone Joint Surg Am. 2015 Sep 2;97(17):1386-97
pubmed: 26333733
Arthritis Care Res (Hoboken). 2013 Feb;65(2):294-8
pubmed: 22807233
Clin Orthop Relat Res. 2016 Mar;474(3):744-51
pubmed: 26552804
World J Surg. 2015 Dec;39(12):2999-3007
pubmed: 26304611
Am J Surg. 2013 Sep;206(3):410-7
pubmed: 23759697
J Orthop Surg Res. 2018 Dec 29;13(1):328
pubmed: 30594233
Ann Rheum Dis. 2018 Feb;77(2):281-288
pubmed: 29097373
PLoS One. 2016 Mar 03;11(3):e0150866
pubmed: 26938768
Osteoarthritis Cartilage. 2017 Nov;25(11):1797-1803
pubmed: 28801208
Neuroendocrinology. 2010;92 Suppl 1:55-9
pubmed: 20829619
Eur J Surg. 2001 May;167(5):351-4; discussion 355
pubmed: 11419550
Adv Orthop. 2016;2016:7268985
pubmed: 28018678
Semin Arthritis Rheum. 2017 Feb;46(4):423-429
pubmed: 27692433
Br J Anaesth. 2017 Aug 1;119(2):267-275
pubmed: 28854533
Pharmacol Ther. 2002 Oct;96(1):23-43
pubmed: 12441176
Am J Surg. 2011 Mar;201(3):305-8; discussion 308-9
pubmed: 21367368
Intensive Care Med. 2015 Jul;41(7):1220-34
pubmed: 26100123
Ann Intensive Care. 2011 Apr 13;1(1):7
pubmed: 21906332
Am J Orthop (Belle Mead NJ). 2018 Dec;47(12):
pubmed: 30650172
Open Rheumatol J. 2013 Nov 29;7:119-24
pubmed: 24454587